Difference between revisions of "Volasertib (BI-6727)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
Warner-admin (talk | contribs) m (Warner-admin moved page Volasertib (BI 6727) to Volasertib (BI-6727) without leaving a redirect) |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Polo-like kinase 1 ([http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=9077 PLK1]) inhibitor | Polo-like kinase 1 ([http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=9077 PLK1]) inhibitor | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[Acute myeloid leukemia]]== | + | ===[[Acute myeloid leukemia]]=== |
| − | # Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. [http://www.bloodjournal.org/content/124/9/1426.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148765/ link to PMC article] [https:// | + | # '''BI 1230.4:''' Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. [http://www.bloodjournal.org/content/124/9/1426.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4148765/ link to PMC article] [https://pubmed.ncbi.nlm.nih.gov/25006120/ PubMed] [https://clinicaltrials.gov/study/NCT00804856 NCT00804856] |
| − | = | + | ==Also known as== |
| − | * | + | *'''Code name:''' BI-6727 |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 15: | Line 15: | ||
[[Category:PLK1 inhibitors]] | [[Category:PLK1 inhibitors]] | ||
| − | [[Category:Acute myeloid leukemia medications]] | + | [[Category:Acute myeloid leukemia medications (investigational)]] |
| − | |||
[[Category:Investigational drugs]] | [[Category:Investigational drugs]] | ||
Latest revision as of 00:48, 29 July 2023
Mechanism of action
Polo-like kinase 1 (PLK1) inhibitor
Preliminary data
Acute myeloid leukemia
- BI 1230.4: Döhner H, Lübbert M, Fiedler W, Fouillard L, Haaland A, Brandwein JM, Lepretre S, Reman O, Turlure P, Ottmann OG, Müller-Tidow C, Krämer A, Raffoux E, Döhner K, Schlenk RF, Voss F, Taube T, Fritsch H, Maertens J. Randomized, phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy. Blood. 2014 Aug 28;124(9):1426-33. Epub 2014 Jul 8. link to original article link to PMC article PubMed NCT00804856
Also known as
- Code name: BI-6727